Skip to main content
Full access
Communications and Updates
Published Online: 1 June 2014

Potentiation of the Effect of Buprenorphine/Naloxone With Gabapentin or Quetiapine

To the Editor: Although it is an effective treatment for opioid dependence, buprenorphine/naloxone may be misused. We report here a case of potentiation of buprenorphine/naloxone with gabapentin and quetiapine.

Case Report

“Mr. A,” a 38-year-old man, began misusing heroin and prescription opioids in his late twenties. After being arrested for drug possession, he completed a treatment program and was placed on probation that stipulated periodic drug screens. He was prescribed buprenorphine (8 mg)/naloxone (2 mg), two films sublingually as a single daily dose. He initially appeared to do well. After presenting to his probation officer in an apparently intoxicated state, he was taken back into custody. His urine drug screen was negative.
Mr. A admitted he had been misusing buprenorphine/naloxone in conjunction with other prescription medications as a partial substitute for illicit opiates. He wanted to maintain negative drug screens but also “still get high.” He described taking buprenorphine/naloxone simultaneously with up to 1,000 mg of quetiapine or with up to 2,400 mg of gabapentin. With buprenorphine/naloxone and either additional medication, he experienced a relaxed euphoric state that was not as intense as with illicit opiates but was still quite desirable. He entered another drug treatment program to address this problem.

Discussion

In a survey carried out in substance misuse clinics, 22% of respondents admitted abusing gabapentin or pregabalin, and of these, 38% abused gabapentanoids to potentiate the high obtained from methadone (1). The possible mechanism of action for the potentiation of an opiate high may be related to gabapentin’s ability to increase the analgesic effect of opiates. Opiates act by bonding to opioid receptors, opening G protein-coupled potassium channels, and closing voltage-dependent calcium channels, thus preventing the release of excitatory amino acids in the spinal cord (2). Gabapentin selectively inhibits voltage-gated calcium channels, increases GABA transmission, and modulates excitatory amino acids at N-methyl-d-aspartic acid receptor sites (3). Thus opiates and gabapentin have certain shared mechanisms affecting analgesia. It has also been hypothesized that an increased analgesic effect of gabapentin and morphine may be contributed to by an increase in gabapentin serum concentration that results from the two medications being given together (2). Gabapentin has demonstrated usefulness in preventing opioid withdrawal, probably by modulating excitatory amino acids, which are increased during withdrawal (3). The interactions of quetiapine’s effects on serotonergic, dopaminergic, and other receptor systems with opiate effects, and possibly nonopiate effects, are speculative.
Clinicians treating opiate-dependent individuals should be aware that some patients may attempt to covertly potentiate the effects of buprenorphine/naloxone by abusing drugs such as gabapentin or quetiapine.

References

1.
Baird CR, Fox P, Colvin LA: Gabapentenoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res 2013; 20:115–118
2.
Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G: Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg 2000; 91:185–191
3.
Salehi M, Kheirabadi GR, Maracy MR, Ranjkesh M: Importance of gabapentin dose in treatment of opioid withdrawal. J Clin Psychopharmacol 2011; 31:593–596

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 691
PubMed: 24880512

History

Accepted: March 2014
Published online: 1 June 2014
Published in print: June 2014

Authors

Affiliations

Roy R. Reeves, D.O., Ph.D.
Mark E. Ladner, M.D.
From the Department of Psychiatry, Jackson VA Medical Center, Jackson, Miss.

Competing Interests

The authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share